1  was able to produce the QUIS effect as does quisqualic acid.

2 -NMDA agonists, kainic acid (0.1-0.2 mM) and quisqualic acid (1-10 mM), into the NMC block locomotion

3 onists N-methyl-D-aspartate (10 microM) or L-quisqualic acid (3 microM).

4 hat is sensitive to the NAALADase inhibitors quisqualic acid and 2-(phosphonomethyl)glutaric acid.

5     Addition of GCP II inhibitors beta-NAAG, quisqualic acid and 2-(phosphonomethyl)pentanedioic acid

6 at was inhibited by the NAALADase inhibitors quisqualic acid and beta-NAAG.

7 nalysis identified the paralytic compound as quisqualic acid (C(5)H(7)N(3)O(5)), a known but rare ago

8             Geranium-derived and synthetic L-quisqualic acid demonstrated the same positive paralytic

9                       The group I agonist, l-quisqualic acid (l-QA), activated the pyloric central pa

10                      Rats received bilateral quisqualic acid lesions of the nucleus basalis magnocell

11                                    Rats with quisqualic acid lesions of the nucleus basalis magnocell

12     Exposure of slices of rat hippocampus to quisqualic acid produces an enhanced sensitivity of neur

13 (phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at

14                The non-NMDA receptor agonist quisqualic acid (QUIS) and NMDA were ionophoresed onto N

15  and for 13-15 weeks after: 1) injections of quisqualic acid (QUIS) into the thoracic gray matter (T8

16 s basalis magnocellularis (nBM) using either quisqualic acid (QUIS) or 192 IgG-saporin (SAP).

17 ies have shown that intraspinal injection of quisqualic acid (QUIS) produces excitotoxic injury with

18 e of the agonists glutamic acid (glutamate), quisqualic acid (quisqualate), and alpha-amino-3-hydroxy

19 ionally constrained cyclobutane analogues of quisqualic acid (Z)- and (E)-1-amino-3-[2'-(3',5'-dioxo-